Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Klotho allele lowers APOE4-associated risk of Alzheimer’s

Publish date:: April 13, 2020

Key clinical point: The klotho genotype known as KL-VS had a protective effect against development of Alzheimer’s disease (AD) in cognitively normal older adult carriers of the APOE4 allele.

Major finding: The presence of the APOE4 allele and heterozygosity for KL-VS significantly reduced risk for developing AD (odds ratio, 0.75) among cognitively normal individuals aged 60-80 years.

Study details: The data come from a case-control study of 22 cohorts including more than 20,000 individuals aged 60-80 years.

Disclosures: The study was supported by the Iqbal Farrukh & Asad Jamal Center for Cognitive Health in Aging, The South Palm Beach County Foundation, and the National Institutes of Health. The researchers had no financial conflicts to disclose.

Citation:

Belloy ME et al. JAMA Neurol. 2020 Apr 13. doi: 10.1001/jamaneurol.2020.0414.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Alzheimer's & Cognition

Vascular dementia risk particularly high in type 2 diabetes,

Mortality burden of dementia may be greater than estimated,

Cognitive deficits complex in youths with type 2 diabetes,

Population study supports migraine-dementia link,

Mixed results for aducanumab in two phase 3 trials for Alzheimer’s disease,